Pharmaceutical giant Pfizer Inc (NYSE:PFE) and immunotherapy company BioNTech SE (Nasdaq:BNTX) announced on Friday that they have won a contract from the Japanese Government to supply 120 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, the virus that causes COVID-19.
Financial details of the agreement with the Ministry of Health, Labour and Welfare were not disclosed.
BNT162 is based on BioNTech's proprietary mRNA technology and supported by Pfizer's global vaccine development and manufacturing capabilities. The vaccine development programme is evaluating at least four experimental vaccine candidates, each of which represents a unique combination of messenger RNA (mRNA) format and target antigen.
The BNT162 vaccine candidates are currently in clinical studies and are not yet approved for distribution anywhere in the world. Two of the four investigational vaccine candidates, BNT162b1 and BNT162b2, recently received Fast Track designation from the US Food and Drug Administration (FDA).
Deliveries of the vaccine candidate to Japan are planned for the first half of 2021, subject to regulatory approval.
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma